| ID Source | ID |
|---|---|
| PubMed CID | 20226 |
| CHEBI ID | 82101 |
| SCHEMBL ID | 118165 |
| MeSH ID | M0041281 |
| Synonym |
|---|
| despirol |
| general chemical 9160 |
| kelevan |
| allied gc 9160 |
| ai3-27154 |
| kelevan [iso] |
| 1,3,4-metheno-1h-cyclobuta(c,d)-pentalene-2-levulinic acid, 1,1a,3,3a,4,5,5a,5b,6-decachlorooctahydro-2-hydroxy-, ethyl ester |
| general chemicals 9160 |
| caswell no. 436c |
| gc 9160 |
| 1,3,4-methano-1h-cyclobuta(cd)pentalene-2-pentanoic acid, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-2-hydroxy-gamma-oxo-, ethyl ester |
| ethyl 1,1a,3,3a,4,5,5a,5b,6-decachlorooctahydro-2-hydroxy-1,3,4-metheno-2h-cyclobuta(cd) pentamethylene-2-levulinate |
| C18962 |
| 4234-79-1 |
| elevat |
| 1,3,4-metheno-1h-cyclobuta(cd)pentalene-2-pentanoic acid, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-2-hydroxy-gamma-oxo-, ethyl ester |
| gc-9160 |
| SCHEMBL118165 |
| CHEBI:82101 |
| DTXSID7058098 |
| 1,3,4-metheno-1h-cyclobuta[cd]pentalene-2-levulinic acid, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-2-hydroxy-, ethyl ester |
| POSKOXIJDWDKPH-UHFFFAOYSA-N |
| 1,3,4-metheno-1h-cyclobuta[cd]pentalene-2-pentanoic acid, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-2-hydroxy-.gamma.-oxo-, ethyl ester |
| kelevan, pestanal(r), analytical standard |
| Q21042454 |
| ethyl 5-(1,2,3,4,6,7,8,9,10,10-decachloro-5-hydroxy-5-pentacyclo[5.3.0.02,6.03,9.04,8]decanyl)-4-oxopentanoate |
| AKOS040744563 |
| Class | Description |
|---|---|
| oxo carboxylic acid | Any compound that has an aldehydic or ketonic group as well as a carboxylic acid group in the same molecule. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (85.71) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.42) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||